Skip to main content
SpringerLink
Log in

ASCO 2023: new treatment options in CNS tumors

Invited short review

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Practice-changing therapy for IDH1/2–mutant diffuse glioma was presented at the meeting. Vorasidenib as an oral, brain penetrant, dual inhibitor of mutant IDH1/2 showed very promising results in the phase 3 INDIGO study. Other new treatment approaches including vaccines, immunotherapy and targeted therapy in rare von Hippel–Lindau-associated cerebral hemangioblastomas have shown progress in neuro-oncology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

2 HG:

2-hydroxyglutarate

CCNU:

Lomustine

IDH:

Isocitrate dehydrogenase

MGMT:

O6-methylguanine methyltransferase

OS:

Overall survival

PBO:

Placebo

PCV:

Procarbazine, CCNU, vincristine

PFS:

Progression-free survival

RANO:

Response Assessment in Neuro-Oncology

TTNI:

Time to next intervention

VOR:

Vorasidenib

References

  1. Yan H, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009;360:765–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hartmann C, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–74.

    Article  PubMed  Google Scholar 

  3. Buckner JC, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374(14):1344–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mellinghoff IK, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023; https://doi.org/10.1056/NEJMoa2304194.

    Article  PubMed  Google Scholar 

  5. Wakimoto H, et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res. 2014;20(11):2898–909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Alden RS. Glutamine metabolism and radiosensitivity: Beyond the Warburg effect. Front Oncol. 2022;12:1070514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. ClinicalTrials.gov Identifier: NCT03922555; ASTX727 in Recurrent/Progressive Non enhancing IDH Mutant Gliomas

  8. ClinicalTrials.gov Identifier: NCT05406700 Niraparib In Recurrent IDH 1/2 Gliomas

Download references

Author information

Authors and Affiliations

  1. Konsiliardienst Innere Medizin und Neuroonkologie, Kepler Universitätsklinikum/Kepler University Hospital, Neuromed Campus, Wagner-Jauregg-Weg 15, 4020, Linz, Austria

    Josef Pichler

Authors
  1. Josef Pichler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Josef Pichler.

Ethics declarations

Conflict of interest

J. Pichler declares that he/she has no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pichler, J. ASCO 2023: new treatment options in CNS tumors. memo 16, 222–224 (2023). https://doi.org/10.1007/s12254-023-00915-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-023-00915-z

Keywords

Search

Navigation